Overview
Corporate Profile
Kips Bay Medical, Inc. was founded in May 2007 to develop innovative therapeutic vascular technologies for the cardiac surgeon. With our first product we are focused on developing, manufacturing and commercializing our external saphenous vein support technology, or eSVS MESH, for use in coronary artery bypass grafting, or CABG, surgery. Our eSVS MESH is a nitinol mesh sleeve that, when placed over a saphenous vein graft during CABG surgery, is designed to improve the structural characteristics and long-term performance of the vein graft.... More >>
Stock Quote
KIPS (Common Stock)
PriceChange% ChangeVolume
$0.58 - 0.023.33%200,882
Exchange: NASDAQ (US Dollar)
Financial Status Indicator: D
04/15/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/17/14Kips Bay Medical Announces FDA Approval for U.S. Expansion of Its eMESH I Clincal Feasibility Study
MINNEAPOLIS, March 17, 2014 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (Nasdaq:KIPS) along with Manny Villafaña, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration ("FDA") has granted an approval for Kips Bay Medical to include more U.S. patients and U.S. study sites in its "eMESH I" clinical feasibility trial of its eSVS® Mesh. In its initial approval, the FDA indicated that it would allow a staged enrollment within the United States, starti... 
Printer Friendly Version
03/12/14Kips Bay Medical Provides Business Update and Reports Fourth Quarter and Full Year 2013 Results
MINNEAPOLIS, March 12, 2014 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery, today provided a business update and announced financial results for its fourth quarter and full year ended December 31, 2013. FDA Update Enrollments and site activations continue in the Kips Bay eMESH I clinical feasibility... 
Printer Friendly Version
02/10/14Kips Bay Medical Announces the First Austrian Implant of the eSVS Mesh
MINNEAPOLIS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Manny Villafaña, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on January 14, 2014, the first commercial implant of the Company's eSVS® Mesh in Austria was performed at the Medical University of Vienna in Vienna, Austria. This implant was performed under the direction of Professor Dr. Günther Laufer. The presiding surgeon in the case, Professor Dr. Sigrid Sandner, commented that the eSVS Mesh was easily deployed with no com... 
Printer Friendly Version
01/29/14Kips Bay Medical Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriters' Over-Allotment Option
MINNEAPOLIS, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS® Mesh, for use in coronary artery bypass grafting surgery, today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and the sale of an additional 785,000 shares of common stock pursuant to the exercise in full by the underwr... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | Financial Tear Sheet Tear Sheet